Tarsus Pharmaceuticals Ownership
| TARS Stock | USD 49.97 0.06 0.12% |
Shares in Circulation | First Issued 2017-12-31 | Previous Quarter 38.4 M | Current Value 37.6 M | Avarage Shares Outstanding 20 M | Quarterly Volatility 11.4 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Tarsus |
Tarsus Stock Ownership Analysis
About 92.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.28. Tarsus Pharmaceuticals recorded a loss per share of 3.07. The entity had not issued any dividends in recent years. Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. Tarsus Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 46 people. To find out more about Tarsus Pharmaceuticals contact the company at 949 409 1801 or learn more at https://www.tarsusrx.com.Besides selling stocks to institutional investors, Tarsus Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Tarsus Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Tarsus Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Tarsus Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Tarsus Pharmaceuticals Insider Trades History
About 8.0% of Tarsus Pharmaceuticals are currently held by insiders. Unlike Tarsus Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Tarsus Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Tarsus Pharmaceuticals' insider trades
Tarsus Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Tarsus Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tarsus Pharmaceuticals backward and forwards among themselves. Tarsus Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Tarsus Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Amvescap Plc. | 2024-12-31 | 932.1 K | State Street Corp | 2024-12-31 | 916.9 K | Geode Capital Management, Llc | 2024-12-31 | 838.8 K | Macquarie Group Ltd | 815.9 K | Artisan Partners Limited Partnership | 2024-12-31 | 691.3 K | Millennium Management Llc | 2024-12-31 | 644 K | Ikarian Capital, Llc | 2024-12-31 | 607.7 K | Ensign Peak Advisors Inc | 2024-12-31 | 570.1 K | Cormorant Asset Management, Llc | 2024-12-31 | 500 K | Blackrock Inc | 2024-12-31 | 3.5 M | Rtw Investments, Llc | 2024-12-31 | 3.2 M |
Tarsus Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tarsus Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tarsus Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tarsus Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Tarsus Pharmaceuticals Outstanding Bonds
Tarsus Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Tarsus Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Tarsus bonds can be classified according to their maturity, which is the date when Tarsus Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Tarsus Pharmaceuticals Corporate Filings
F4 | 20th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 18th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 13th of March 2025 Other Reports | ViewVerify | |
| 13th of February 2025 Other Reports | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Tarsus Stock Analysis
When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.